From Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World Evidence
Schiabor Barrett, K. M.; Ferber, M. J.; Candille, S.; Thibodeau, I.; Iacoboni, D.; Sturm, A. C.; Haldeman-Englert, C.; Powell, S. F.; Stoller, D.; Chapman, C. N.; Chahal, C. A. A.; Judge, D. P.; Olson, D. A.; Grzymski, J. J.; Washington, N. L.; Hajek, C.; Lee, W.; Bolze, A.; Lu, J. T.; Cirulli, E. T.
Show abstract
The clinical utility of genomic testing is constrained by variants of uncertain significance (VUS), which complicate diagnostic interpretation and patient management. The ACMG/AMP PS4 criterion, "prevalence in affected individuals statistically increased compared to controls," offers strong evidence for pathogenicity but is often challenging to apply due to the limited availability of robust, matched case-control genomic and phenotypic data. Further, there are currently no options available to score evidence from case-control studies towards benignity. We propose and validate a new code, RWE (real world evidence), by integrating de-identified, longitudinal clinical data with variant carriers and non-carriers identified from exome or genome sequence data across three large-scale clinicogenomic datasets: the Helix Research Network (HRN) dataset, UK Biobank (UKB) and All of US (AoU). Phenotypes for established gene-level disease associations were compiled from the longitudinal medical records of the individuals, enabling rigorous variant-specific case-control analyses from population data. This RWE approach was systematically applied to all variants, including previously identified VUS in clinically relevant genes, powering our VUS Early Surveillance Platform. Across 20 hereditary cancer and cardiovascular genes, the application of RWE provided sufficient evidence to reclassify a VUS in 32% of VUS carriers-99.7% to B/LB and 0.3% to P/LP-directly resolving their ambiguous status. This reclassification rate varied by gene, ranging from 0.7% for BRCA2 up to 50% for LDLR. The systematic integration of Real-World Evidence from large-scale clinicogenomic datasets into the ACMG/AMP scoring rubric through our newly developed and statistically robust RWE category is a significant improvement to variant interpretation that is projected to resolve over 50% of VUS carriers once longitudinal clinico-genomic databases are available for ~3M individuals. This approach markedly reduces the burden of Variants of Uncertain Significance, provides more definitive diagnoses for a substantial proportion of previously unresolved cases, and ultimately increases the clinical utility and adoption of genomic testing, representing a critical advancement for precision medicine.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Informing Variant Assessment using Structured Evidence from Prior Classifications (PS1, PM5, and PVS1 Sequence Variant Interpretation Criteria) 97%
- A Framework for Automated Gene Selection in Genomic Screening 97%
- Assessment of the variant prioritisation strategy for genomic newborn screening in the Generation Study 96%
Similar papers in this journal
- Extracting and calibrating evidence of variant pathogenicity from population biobank data 98%
- Availability of benign missense variant “truthsets” for validation of functional assays: current status and a novel systematic approach 97%
- Identification of actionable genetic variants in 4,198 Scottish volunteers from the Viking Genes research cohort and implementation of return of results 97%
Similar papers in this journal
- Long-read genome sequencing for the diagnosis of neurodevelopmental disorders 95%
- Inclusion of Variants Discovered from Diverse Populations Improves Polygenic Risk Score Transferability 95%
- IMPROVE-DD: Integrating Multiple Phenotype Resources Optimises Variant Evaluation in genetically determined Developmental Disorders 94%
Similar papers in this journal
- A systematic analysis of splicing variants identifies new diagnoses in the 100,000 Genomes Project. 96%
- Evaluating Genome Sequencing Strategies: Trio, Singleton, and Standard Testing in Rare Disease Diagnosis 95%
- Recommendations for clinical interpretation of variants found in non-coding regions of the genome 95%
Similar papers in this journal
- Combining rare and common genetic variants improves population risk stratification for breast cancer 95%
- Genetic Diagnosis of Facioscapulohumeral Muscular Dystrophy Type 1 Using Rare Variant Linkage Analysis and Long Read Genome Sequencing 94%
- The impact of the Turkish (TK) population variome on the genomic architecture of rare disease traits 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.